RS BioTherapeutics Appoints Pharmaceutical and Consumer Products Veteran Curtis R. Rhine as Its Chief Financial Officer
17. April 2023 10:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., April 17, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
RS BioTherapeutics Appoints Pharmaceutical Industry Veteran Dean Hart as Chief Executive Officer
10. April 2023 11:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., April 10, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
RS BioTherapeutics Selects Recipharm as Product Characterization Partner
14. November 2022 10:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS BioTherapeutics Secures $3 Million Seed II Round of Funding
26. September 2022 09:34 ET
|
RS BioTherapeutics
CUMBERLAND, Md., Sept. 26, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS Biotherapeutics Appoints Jeremy Plumb as Chief Cultivation Officer
01. August 2022 10:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., Aug. 01, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound
11. Juli 2022 11:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., July 11, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and...
RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound
23. Mai 2022 11:00 ET
|
RS BioTherapeutics
CUMBERLAND, Md., May 23, 2022 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system to research, develop and...